Analysts Set Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Price Target at $294.50

Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) has earned an average recommendation of “Moderate Buy” from the twenty-four research firms that are presently covering the firm, MarketBeat.com reports. One research analyst has rated the stock with a sell recommendation, five have given a hold recommendation and eighteen have given a buy recommendation to the company. The average 12 month price objective among brokerages that have issued a report on the stock in the last year is $298.09.

A number of equities analysts have commented on ALNY shares. The Goldman Sachs Group raised Alnylam Pharmaceuticals from a “neutral” rating to a “buy” rating and boosted their price objective for the stock from $198.00 to $370.00 in a research note on Friday, August 16th. HC Wainwright reissued a “buy” rating and issued a $400.00 price objective on shares of Alnylam Pharmaceuticals in a research note on Monday. Cantor Fitzgerald reissued a “neutral” rating and issued a $220.00 price objective on shares of Alnylam Pharmaceuticals in a research note on Friday, October 11th. JPMorgan Chase & Co. boosted their price objective on Alnylam Pharmaceuticals from $248.00 to $280.00 and gave the stock a “neutral” rating in a research note on Monday, August 26th. Finally, Barclays boosted their price objective on Alnylam Pharmaceuticals from $295.00 to $329.00 and gave the stock an “overweight” rating in a research note on Friday, November 1st.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently modified their holdings of ALNY. Allspring Global Investments Holdings LLC boosted its position in shares of Alnylam Pharmaceuticals by 572.0% during the first quarter. Allspring Global Investments Holdings LLC now owns 168 shares of the biopharmaceutical company’s stock worth $25,000 after buying an additional 143 shares during the period. Janney Montgomery Scott LLC boosted its position in Alnylam Pharmaceuticals by 47.4% during the first quarter. Janney Montgomery Scott LLC now owns 2,775 shares of the biopharmaceutical company’s stock valued at $415,000 after purchasing an additional 892 shares during the last quarter. ProShare Advisors LLC boosted its position in Alnylam Pharmaceuticals by 10.1% during the first quarter. ProShare Advisors LLC now owns 8,827 shares of the biopharmaceutical company’s stock valued at $1,319,000 after purchasing an additional 809 shares during the last quarter. Mitsubishi UFJ Asset Management Co. Ltd. boosted its position in Alnylam Pharmaceuticals by 22.5% during the first quarter. Mitsubishi UFJ Asset Management Co. Ltd. now owns 68,790 shares of the biopharmaceutical company’s stock valued at $10,281,000 after purchasing an additional 12,646 shares during the last quarter. Finally, Intech Investment Management LLC boosted its position in Alnylam Pharmaceuticals by 44.3% during the first quarter. Intech Investment Management LLC now owns 10,885 shares of the biopharmaceutical company’s stock valued at $1,627,000 after purchasing an additional 3,344 shares during the last quarter. 92.97% of the stock is owned by institutional investors and hedge funds.

Alnylam Pharmaceuticals Price Performance

Shares of ALNY stock opened at $232.27 on Friday. The stock’s fifty day simple moving average is $274.53 and its 200 day simple moving average is $236.10. The company has a debt-to-equity ratio of 31.64, a current ratio of 2.75 and a quick ratio of 2.69. The firm has a market cap of $29.96 billion, a price-to-earnings ratio of -88.65 and a beta of 0.39. Alnylam Pharmaceuticals has a one year low of $141.98 and a one year high of $304.39.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last announced its quarterly earnings results on Thursday, October 31st. The biopharmaceutical company reported ($0.87) EPS for the quarter, missing the consensus estimate of ($0.51) by ($0.36). The company had revenue of $500.90 million during the quarter, compared to analyst estimates of $532.91 million. Alnylam Pharmaceuticals’s quarterly revenue was down 33.3% compared to the same quarter last year. During the same quarter last year, the company posted $1.15 earnings per share. On average, analysts expect that Alnylam Pharmaceuticals will post -2.22 earnings per share for the current fiscal year.

Alnylam Pharmaceuticals Company Profile

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.